Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: AKAP13

Gene summary for AKAP13

Gene summary.

Gene information	Species	Human
	Gene symbol	AKAP13
	Gene ID	11214
	Gene name	A-kinase anchoring protein 13
	Gene Alias	AKAP-13
	Cytomap	15q25.3
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	A8MYJ1

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
11214	AKAP13	CA_HPV_1	Human	Cervix	CC	3.37e-04	3.75e-02	0.0264
11214	AKAP13	CCI_1	Human	Cervix	CC	1.47e-09	2.09e+00	0.528
11214	AKAP13	CCI_2	Human	Cervix	CC	1.11e-23	1.48e+00	0.5249
11214	AKAP13	CCI_3	Human	Cervix	CC	1.25e-14	1.37e+00	0.516
11214	AKAP13	Tumor	Human	Cervix	CC	3.37e-08	-3.14e-01	0.1241
11214	AKAP13	sample3	Human	Cervix	CC	4.69e-06	-1.34e-01	0.1387
11214	AKAP13	L1	Human	Cervix	CC	2.87e-02	-2.36e-01	0.0802
11214	AKAP13	T3	Human	Cervix	CC	6.23e-04	-1.95e-01	0.1389
11214	AKAP13	HTA11_3410_2000001011	Human	Colorectum	AD	7.69e-30	-7.27e-01	0.0155
11214	AKAP13	HTA11_347_2000001011	Human	Colorectum	AD	4.22e-07	4.84e-01	-0.1954
11214	AKAP13	HTA11_411_2000001011	Human	Colorectum	SER	1.49e-05	7.28e-01	-0.2602
11214	AKAP13	HTA11_3361_2000001011	Human	Colorectum	AD	4.52e-02	-4.36e-01	-0.1207
11214	AKAP13	HTA11_5216_2000001011	Human	Colorectum	SER	1.48e-03	-4.68e-01	-0.1462
11214	AKAP13	HTA11_9341_2000001011	Human	Colorectum	SER	1.68e-06	-7.78e-01	-0.00410000000000005
11214	AKAP13	HTA11_866_3004761011	Human	Colorectum	AD	3.35e-04	-4.13e-01	0.096
11214	AKAP13	HTA11_9408_2000001011	Human	Colorectum	AD	1.98e-06	-6.97e-01	0.0451
11214	AKAP13	HTA11_8622_2000001021	Human	Colorectum	SER	1.16e-03	-3.96e-01	0.0528
11214	AKAP13	HTA11_10711_2000001011	Human	Colorectum	AD	2.71e-10	-6.10e-01	0.0338
11214	AKAP13	HTA11_7696_3000711011	Human	Colorectum	AD	1.58e-05	-3.55e-01	0.0674
11214	AKAP13	HTA11_7469_2000001011	Human	Colorectum	AD	4.43e-03	-6.08e-01	-0.0124

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:003297010	Cervix	CC	regulation of actin filament-based process	96/2311	397/18723	4.00e-11	8.54e-09	96
GO:190290310	Cervix	CC	regulation of supramolecular fiber organization	92/2311	383/18723	1.49e-10	2.48e-08	92
GO:003295610	Cervix	CC	regulation of actin cytoskeleton organization	86/2311	358/18723	5.90e-10	7.51e-08	86
GO:00510566	Cervix	CC	regulation of small GTPase mediated signal transduction	75/2311	302/18723	1.54e-09	1.74e-07	75
GO:003367410	Cervix	CC	positive regulation of kinase activity	101/2311	467/18723	8.66e-09	7.22e-07	101
GO:00072656	Cervix	CC	Ras protein signal transduction	79/2311	337/18723	9.49e-09	7.77e-07	79
GO:00069139	Cervix	CC	nucleocytoplasmic transport	71/2311	301/18723	4.04e-08	2.54e-06	71
GO:00511699	Cervix	CC	nuclear transport	71/2311	301/18723	4.04e-08	2.54e-06	71
GO:00458608	Cervix	CC	positive regulation of protein kinase activity	85/2311	386/18723	5.61e-08	3.29e-06	85
GO:00719007	Cervix	CC	regulation of protein serine/threonine kinase activity	75/2311	359/18723	2.76e-06	8.02e-05	75
GO:00160498	Cervix	CC	cell growth	92/2311	482/18723	1.16e-05	2.49e-04	92
GO:00072666	Cervix	CC	Rho protein signal transduction	35/2311	137/18723	1.77e-05	3.33e-04	35
GO:00511689	Cervix	CC	nuclear export	38/2311	154/18723	1.86e-05	3.46e-04	38
GO:00719025	Cervix	CC	positive regulation of protein serine/threonine kinase activity	46/2311	200/18723	1.87e-05	3.47e-04	46
GO:00465785	Cervix	CC	regulation of Ras protein signal transduction	44/2311	189/18723	2.05e-05	3.73e-04	44
GO:00434104	Cervix	CC	positive regulation of MAPK cascade	90/2311	480/18723	2.92e-05	4.83e-04	90
GO:00431228	Cervix	CC	regulation of I-kappaB kinase/NF-kappaB signaling	53/2311	249/18723	4.50e-05	6.87e-04	53
GO:011002010	Cervix	CC	regulation of actomyosin structure organization	27/2311	100/18723	5.55e-05	8.10e-04	27
GO:00605375	Cervix	CC	muscle tissue development	76/2311	403/18723	9.76e-05	1.27e-03	76
GO:00310329	Cervix	CC	actomyosin structure organization	43/2311	196/18723	1.11e-04	1.40e-03	43

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa05163	Colorectum	AD	Human cytomegalovirus infection	75/2092	225/8465	2.00e-03	1.10e-02	7.01e-03	75
hsa04928	Colorectum	AD	Parathyroid hormone synthesis, secretion and action	38/2092	106/8465	6.60e-03	2.77e-02	1.76e-02	38
hsa051631	Colorectum	AD	Human cytomegalovirus infection	75/2092	225/8465	2.00e-03	1.10e-02	7.01e-03	75
hsa049281	Colorectum	AD	Parathyroid hormone synthesis, secretion and action	38/2092	106/8465	6.60e-03	2.77e-02	1.76e-02	38
hsa049282	Colorectum	SER	Parathyroid hormone synthesis, secretion and action	31/1580	106/8465	5.20e-03	3.28e-02	2.38e-02	31
hsa051632	Colorectum	SER	Human cytomegalovirus infection	57/1580	225/8465	7.40e-03	3.84e-02	2.79e-02	57
hsa049283	Colorectum	SER	Parathyroid hormone synthesis, secretion and action	31/1580	106/8465	5.20e-03	3.28e-02	2.38e-02	31
hsa051633	Colorectum	SER	Human cytomegalovirus infection	57/1580	225/8465	7.40e-03	3.84e-02	2.79e-02	57
hsa051634	Colorectum	MSS	Human cytomegalovirus infection	74/1875	225/8465	1.12e-04	1.01e-03	6.19e-04	74
hsa049284	Colorectum	MSS	Parathyroid hormone synthesis, secretion and action	37/1875	106/8465	1.72e-03	9.13e-03	5.59e-03	37
hsa051635	Colorectum	MSS	Human cytomegalovirus infection	74/1875	225/8465	1.12e-04	1.01e-03	6.19e-04	74
hsa049285	Colorectum	MSS	Parathyroid hormone synthesis, secretion and action	37/1875	106/8465	1.72e-03	9.13e-03	5.59e-03	37
hsa051636	Colorectum	FAP	Human cytomegalovirus infection	55/1404	225/8465	1.42e-03	7.67e-03	4.67e-03	55
hsa049286	Colorectum	FAP	Parathyroid hormone synthesis, secretion and action	29/1404	106/8465	3.37e-03	1.44e-02	8.77e-03	29
hsa051637	Colorectum	FAP	Human cytomegalovirus infection	55/1404	225/8465	1.42e-03	7.67e-03	4.67e-03	55
hsa049287	Colorectum	FAP	Parathyroid hormone synthesis, secretion and action	29/1404	106/8465	3.37e-03	1.44e-02	8.77e-03	29
hsa051638	Colorectum	CRC	Human cytomegalovirus infection	45/1091	225/8465	1.54e-03	1.17e-02	7.94e-03	45
hsa049288	Colorectum	CRC	Parathyroid hormone synthesis, secretion and action	24/1091	106/8465	3.71e-03	2.29e-02	1.55e-02	24
hsa051639	Colorectum	CRC	Human cytomegalovirus infection	45/1091	225/8465	1.54e-03	1.17e-02	7.94e-03	45
hsa049289	Colorectum	CRC	Parathyroid hormone synthesis, secretion and action	24/1091	106/8465	3.71e-03	2.29e-02	1.55e-02	24

Page: 1 2 3

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

AKAP13

SNV

Missense_Mutation

c.5207N>T

p.Pro1736Leu

p.P1736L

Q12802

protein_coding

deleterious(0.03)

benign(0.015)

TCGA-A2-A0CL-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cytoxan

AKAP13

SNV

Missense_Mutation

c.4555G>A

p.Glu1519Lys

p.E1519K

Q12802

protein_coding

deleterious(0.01)

probably_damaging(0.994)

TCGA-A2-A0YD-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

AKAP13

SNV

Missense_Mutation

c.8128N>C

p.Glu2710Gln

p.E2710Q

Q12802

protein_coding

tolerated(0.07)

possibly_damaging(0.892)

TCGA-A2-A3XY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

AKAP13

SNV

Missense_Mutation

novel

c.2128N>A

p.Glu710Lys

p.E710K

Q12802

protein_coding

deleterious_low_confidence(0.01)

benign(0.003)

TCGA-A2-A4RW-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

AKAP13

SNV

Missense_Mutation

rs747774362

c.2233G>T

p.Asp745Tyr

p.D745Y

Q12802

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.875)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

AKAP13

SNV

Missense_Mutation

novel

c.3318G>T

p.Glu1106Asp

p.E1106D

Q12802

protein_coding

deleterious_low_confidence(0.01)

benign(0.007)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

AKAP13

SNV

Missense_Mutation

rs768166553

c.1220G>A

p.Cys407Tyr

p.C407Y

Q12802

protein_coding

deleterious(0.02)

benign(0.003)

TCGA-AN-A0FX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

AKAP13

SNV

Missense_Mutation

c.1078G>A

p.Val360Ile

p.V360I

Q12802

protein_coding

tolerated(0.42)

benign(0.003)

TCGA-AO-A0JD-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

AKAP13

SNV

Missense_Mutation

rs748198504

c.2512N>T

p.Arg838Trp

p.R838W

Q12802

protein_coding

deleterious_low_confidence(0.02)

benign(0.01)

TCGA-B6-A0IK-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

AKAP13

SNV

Missense_Mutation

novel

c.1228A>C

p.Lys410Gln

p.K410Q

Q12802

protein_coding

deleterious(0.02)

benign(0.332)

TCGA-E2-A15M-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
11214	AKAP13	KINASE		haloperidol	HALOPERIDOL	27023437

Page: 1